Literature DB >> 27177312

The curious origins of angioimmunoblastic T-cell lymphoma.

José R Cortés1, Teresa Palomero.   

Abstract

PURPOSE OF REVIEW: Once an obscure disease, recent studies have transformed our understanding of angioimmunoblastic T-cell lymphoma (AITL). In this review, we summarize new major advances in the genetics and biology of AITL. RECENT
FINDINGS: Genome wide sequencing studies have dissected the repertoire of the genetic alterations driving AITL uncovering a highly recurrent Gly17Val somatic mutation in the small GTPase RHOA and major role for mutations in epigenetic regulators, such as TET2, DNMT3A and IDH2, and signaling factors (e.g., FYN and CD28). These findings support a multistep model of follicular T helper cell transformation in AITL and pinpoint novel candidates for the development of targeted therapies in this disease.
SUMMARY: AITL originates from follicular T helper cells and is characterized by the presence of RHOA G17V mutation together with genetic alterations in TET2, DNMT3A, and IDH2. Research efforts now focus on the elucidation of the specific roles and interplay of these genetic alterations in the pathogenesis of AITL.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27177312      PMCID: PMC5499521          DOI: 10.1097/MOH.0000000000000261

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  116 in total

1.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

2.  Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells.

Authors:  Andrew M Platt; Vivienne B Gibson; Agapitos Patakas; Robert A Benson; Steven G Nadler; James M Brewer; Iain B McInnes; Paul Garside
Journal:  J Immunol       Date:  2010-07-02       Impact factor: 5.422

3.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 4.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas.

Authors:  Marta Cuadros; Sandeep S Dave; Elaine S Jaffe; Emiliano Honrado; Roger Milne; Javier Alves; Jose Rodríguez; Magdalena Zajac; Javier Benitez; Louis M Staudt; Beatriz Martinez-Delgado
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

7.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

Review 8.  TET family proteins and their role in stem cell differentiation and transformation.

Authors:  Luisa Cimmino; Omar Abdel-Wahab; Ross L Levine; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2011-09-02       Impact factor: 24.633

9.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

Review 10.  Metabolic consequences of oncogenic IDH mutations.

Authors:  Seth J Parker; Christian M Metallo
Journal:  Pharmacol Ther       Date:  2015-05-05       Impact factor: 13.400

View more
  16 in total

Review 1.  Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies.

Authors:  Chan-Wang J Lio; Hiroshi Yuita; Anjana Rao
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

2.  Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.

Authors:  Hongxiang Zeng; Hailan He; Lei Guo; Jia Li; Minjung Lee; Wei Han; Anna G Guzman; Shengbing Zang; Yubin Zhou; Xiaotian Zhang; Margaret A Goodell; Katherine Y King; Deqiang Sun; Yun Huang
Journal:  Cancer Lett       Date:  2019-09-26       Impact factor: 8.679

3.  Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.

Authors:  Shengbing Zang; Jia Li; Haiyan Yang; Hongxiang Zeng; Wei Han; Jixiang Zhang; Minjung Lee; Margie Moczygemba; Sevinj Isgandarova; Yaling Yang; Yubin Zhou; Anjana Rao; M James You; Deqiang Sun; Yun Huang
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 4.  The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.

Authors:  Mariano G Cardenas; Erin Oswald; Wenbo Yu; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

Review 5.  Update on recurrent mutations in angioimmunoblastic T-cell lymphoma.

Authors:  Daniel Dai Yu; Jianzhong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2021-12-15

6.  Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.

Authors:  Thomas A Rasmussen; James McMahon; J Judy Chang; Jori Symons; Michael Roche; Ashanti Dantanarayana; Afam Okoye; Bonnie Hiener; Sarah Palmer; Wen Shi Lee; Stephen J Kent; Carrie Van Der Weyden; H Miles Prince; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2017-08-24       Impact factor: 4.177

Review 7.  Clonal evolution in leukemia.

Authors:  Adolfo A Ferrando; Carlos López-Otín
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

8.  Targeting epigenetic regulators in the treatment of T-cell lymphoma.

Authors:  Nada Ahmed; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2020-01-22       Impact factor: 2.929

9.  Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome).

Authors:  Joanna Mangana; Emmanuella Guenova; Katrin Kerl; Mirjana Urosevic-Maiwald; Valerie C Amann; Cornelia Bayard; Reinhard Dummer; Lars E French
Journal:  Case Rep Dermatol       Date:  2017-03-21

Review 10.  Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.

Authors:  José R Cortés; Teresa Palomero
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.